[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American Journal of …, 2016 - infona.pl
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American Journal …, 2015 - europepmc.org
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - American Journal of …, 2016 - hero.epa.gov
Abstract Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9,
significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 …
significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 …
[HTML][HTML] A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - American Journal of …, 2016 - ajconline.org
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
[PDF][PDF] A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - J Cardiol, 2016 - core.ac.uk
Methods Eligible patients (aged! 20 and 85 years) from study sites in Japan were at high risk
for CV events based on Japan Atherosclerosis Society (JAS) criteria. 17 JAS criteria used for …
for CV events based on Japan Atherosclerosis Society (JAS) criteria. 17 JAS criteria used for …
[PDF][PDF] A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - J Cardiol, 2016 - cyberleninka.org
Methods Eligible patients (aged! 20 and 85 years) from study sites in Japan were at high risk
for CV events based on Japan Atherosclerosis Society (JAS) criteria. 17 JAS criteria used for …
for CV events based on Japan Atherosclerosis Society (JAS) criteria. 17 JAS criteria used for …
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - … American Journal of …, 2016 - search.proquest.com
Abstract Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9,
significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 …
significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 …
[引用][C] A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American Journal …, 2016 - cir.nii.ac.jp
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High
Cardiovascular Risk | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Cardiovascular Risk | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
A Kiyosue, N Honarpour, C Kurtz… - The American …, 2016 - pubmed.ncbi.nlm.nih.gov
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …